Evidence map›Paper›PMID 38956624›Full record

ArticleOrphanet journal of rare diseases2024

Safety and efficacy of COVID-19 vaccination in the Chinese population with pulmonary lymphangioleiomyomatosis: a single-center retrospective study.

Weilin Wang, Jingdong Zhou, Xuetao Kong, Yixuan Wang, Qixian Wu, Xiaoqing Gong, Jingye Tai, Yingxin Pan, Hongyuan Huang, Zhen Zhao and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Orphanet journal of rare diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Weilin Wang *Nanshan College, Guangzhou Medical University, Guangzhou, China.
Jingdong Zhou *Nanshan College, Guangzhou Medical University, Guangzhou, China.
Xuetao Kong *School of Public Health, Guangzhou Medical University, Guangzhou, China.
Yixuan WangNanshan College, Guangzhou Medical University, Guangzhou, China.
Qixian WuNanshan College, Guangzhou Medical University, Guangzhou, China.
Xiaoqing GongFirst Clinical College, Guangzhou Medical University, Guangzhou, China.
Jingye TaiNanshan College, Guangzhou Medical University, Guangzhou, China.
Yingxin PanDepartment of Respiratory and Critical Care Medicine, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Diseases, National Clinical Medical Research Center for Respiratory Diseases, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Hongyuan HuangDepartment of Respiratory and Critical Care Medicine, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Diseases, National Clinical Medical Research Center for Respiratory Diseases, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Zhen ZhaoDepartment of Respiratory and Critical Care Medicine, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Diseases, National Clinical Medical Research Center for Respiratory Diseases, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Mei JiangDepartment of Respiratory and Critical Care Medicine, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Diseases, National Clinical Medical Research Center for Respiratory Diseases, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. jiangmei927@163.com.
Jie LiuDepartment of Respiratory and Critical Care Medicine, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Diseases, National Clinical Medical Research Center for Respiratory Diseases, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. ljgird001@163.com.ORCID 0000-0003-3759-9056

Funding

Natural Science Foundation of Guangdong Province 2021A1515011352, 2023A1515010308the Key Project of Independent Subjects Funding of the Guangzhou Institute of Respiratory Health ZNSA-2020013the Project of 2022 Student Innovation Ability Enhancement Program of Guangzhou Medical University 02-408-2203-2106
6 · The paper itself

Abstract

backgroundThe safety and efficacy of vaccination against coronavirus disease 2019 (COVID-19) in patients with lymphangioleiomyomatosis (LAM) is still unclear. This study investigates COVID-19 vaccine hesitancy, vaccine safety and efficacy, and COVID-19 symptoms in LAM patients.

resultsIn total, 181 LAM patients and 143 healthy individuals responded to the questionnaire. The vaccination rate of LAM patients was 77.34%, and 15.7% of vaccinated LAM patients experienced adverse events. Vaccination decreased the risk of LAM patients developing anorexia [OR: 0.17, 95% CI: (0.07, 0.43)], myalgia [OR: 0.34, 95% CI: (0.13, 0.84)], and ageusia [OR: 0.34, 95% CI: (0.14, 0.84)]. In LAM patients, a use of mTOR inhibitors reduced the risk of developing symptoms during COVID-19, including fatigue [OR: 0.18, 95% CI: (0.03, 0.95)], anorexia [OR: 0.30, 95% CI: (0.09, 0.96)], and ageusia [OR: 0.20, 95% CI: (0.06, 0.67)].

conclusionsVaccination rates in the LAM population were lower than those in the general population, as 22.7% (41/181) of LAM patients had hesitations regarding the COVID-19 vaccine. However, the safety of COVID-19 vaccination in the LAM cohort was comparable to the healthy population, and COVID-19 vaccination decreased the incidence of COVID-19 symptoms in LAM patients. In addition, mTOR inhibitors seem not to determine a greater risk of complications in patients with LAM during COVID-19.

Indexed as

COVID-19COVID-19 VaccinesLymphangioleiomyomatosisAdultChinaEast Asian PeopleFemaleHumansLung DiseasesMaleMiddle AgedRetrospective StudiesSARS-CoV-2VaccinationCOVID-19 VaccinesCOVID-19LymphangioleiomyomatosismTOR inhibitorsOmicron variantVaccine

Identifiers

PMID38956624
PMCPMC11220960

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.